LakeShore Biopharma Co Debt to Equity

LakeShore Biopharma Co's debt-to-equity ratio stands at 0.84. That is above the sector sector average of 0.2. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

LakeShore Biopharma Co sits higher the its sector benchmark (0.2) with a debt-to-equity ratio of 0.84. That is roughly 317.3% above the sector mean. Peer context matters because what looks expensive or cheap in absolute terms can be normal for the sector.

Whether 0.84 is attractive depends on LakeShore Biopharma Co's earnings outlook, competitive position, and how peers are valued. Investors typically ask: is growth accelerating, are margins stable, and is the multiple expanding or compressing over time? The history and comparison charts below are built for those checks.

The history chart shows how LakeShore Biopharma Co's debt-to-equity ratio evolved across reporting periods, while the comparison chart places LSB next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.